Clark Capital Management Group’s Ligand Pharmaceuticals LGND Stock Holding History

Clark Capital Management Group’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.4M	Sell	32,948 -57,258	-63%	-$13.5M	0.06%	199
2026 Q1	$18M	Buy	90,206 +10,428	+13%	+$2.06M	0.11%	152
2025 Q4	$15.1M	Sell	79,778 -3,213	-4%	-$617K	0.09%	147
2025 Q3	$14.7M	Buy	82,991 +11,858	+17%	+$1.76M	0.09%	152
2025 Q2	$8.09M	Buy	71,133 +27,079	+61%	+$2.89M	0.06%	168
2025 Q1	$4.63M	Buy	44,054 +6,777	+18%	+$766K	0.03%	202
2024 Q4	$3.99M	Buy	37,277 +11,456	+44%	+$1.3M	0.03%	217
2024 Q3	$2.58M	Buy	+25,821	New	+$2.6M	0.02%	237

Other funds holding LGND

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Clark Capital Management Group's LGND Position: Q2 2026 in Review

Clark Capital Management Group reduced its Ligand Pharmaceuticals (LGND) stake by 63% in Q2 2026, selling an estimated $13.5M and leaving 32,948 shares worth $10.4M. The position accounts for 0.06% of the portfolio, ranked #199.

Clark Capital Management Group first reported a position in LGND in Q3 2024 and has held it in 8 quarters since. The position peaked at $18M in Q1 2026. 417 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

Clark Capital Management Group held 32,948 shares of Ligand Pharmaceuticals worth $10.4M as of Q2 2026.
Clark Capital Management Group sold 57,258 Ligand Pharmaceuticals shares in Q2 2026, an estimated $13.5M.
Ligand Pharmaceuticals made up 0.06% of Clark Capital Management Group's portfolio in Q2 2026, its #199 holding.
Clark Capital Management Group first reported a position in Ligand Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
Clark Capital Management Group's Ligand Pharmaceuticals position peaked at $18M in Q1 2026.
417 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Clark Capital Management Group's 13F filing for Q2 2026, filed 11 Aug 2026.